CA-QUANERGY-SYSTEMS
30.6.2020 15:02:10 CEST | Business Wire | Press release
Quanergy Systems, Inc. , a leading provider of LiDAR (Light Detection and Ranging) sensors and smart perception solutions, today announced the first commercial integration of 3D AI-powered LiDAR solutions with the Genetec Inc. (“Genetec”) Security Center unified security platform. The integrated solutions will provide advanced people flow and occupancy management in smart spaces as well as enhanced threat detection and surveillance in high-security environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005262/en/
Quanergy’s high-performance AI-powered 3D LiDAR solution will be integrated to the Genetec unified security platform, allowing its use in multiple specialized Security Center modules including Restricted Security Area, Passenger Flow Analytics, and Occupancy Management package to help automate security, people counting and social distancing applications. Adding Quanergy’s 3D LiDAR and sensor data flow to Genetec Security Center provides increased real-time accuracy for a clearer read on actual footfall traffic, occupancy and proximity in a wide variety of industrial applications from transit systems, airports and industrial facilities to public facing businesses including banking and retail.
“Quanergy’s LiDAR flow management solutions bring a new level of real-time 3D insights that make them ideal for any environment where high accuracy and operational intelligence are critical,” said Enzo Signore, CMO at Quanergy. “Our tight integration with the Genetec Security Center unified platform enables a unique level of automation of many applications across retail, critical infrastructure, airport, seaport, enterprise, and smart cities.”
“We are excited to be integrating Quanergy's 3D LiDAR flow management solutions within Genetec Security Center,” said David Lenot, Airport Product Leader at Genetec. “By bringing their 3D LiDAR sensor data into the traffic and passenger flow modules in our unified platform, we’re helping airports and other organizations address pressing needs while also unlocking new insights into their security operations.”
Quanergy’s AI-powered LiDAR solution accurately and reliably monitor wide areas in real-time in a variety of environments without compromising people’s privacy. The new integrated 3D LiDAR-based solutions will provide:
- 98%+ detection accuracy: Quanergy QORTEX People Counter accurately detects the number and direction of people, entering in and out of common areas. This can also be used to detect tailgating and increase the security of critical areas. QORTEX People Counter accuracy is significantly higher than camera-based system.
- Dramatic reduction in false alarms: Quanergy’s QORTEX DTC solution significantly reduces false alarms typical of camera-based systems due to its advanced object detection, tracking, and classification capabilities.
- 5X - 20X lower TCO (total cost of ownership) than camera-based systems due to very wide coverage (360 degree) and long range (40-70m). A single sensor can cover the area upwards of 8000 m2 . This broad area coverage also reduces installation and cabling costs.
- Rich 3D, real-time data: Quanergy’s flow management solutions provide accurate centimeter level information about the number of objects, their spatial location, direction, and speed. Quanergy solutions also can detect distance between people to accurately monitor and manage social distancing policies.
- Privacy protection without compromising or storing private personal information. The LiDAR solutions do not use facial recognition technology nor require opt-in by users; they therefore guarantee the anonymity of people and pose zero PII risk.
- Reliable & Scalable: Works in all lighting and atmospheric conditions so security systems can effectively operate 24/7.
The integrated solutions are available and can be ordered immediately.
For more information, please visit us at www.quanergy.com/contact .
About Quanergy
Quanergy was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers a high-performance AI-powered LiDAR platform designed to accelerate the automation of key business processes to increase productivity, efficiency, and safety of our 3D world. By providing actionable insights to organizations across major industries including, mapping, security, smart cities and smart spaces, industrial automation and transportation, Quanergy is enabling its partners and their end-users to deploy innovative solutions to drive their business growth and ultimately, improve the quality of life for people around the world. For more information, visit www.quanergy.com .
© Genetec Inc., 2020. Genetec, Security Center and the Genetec logo are trademarks of Genetec Inc. and may be registered or pending registration in several jurisdictions. Other trademarks used in this document may be trademarks of the manufacturers or vendors of the respective product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005262/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
